Atossa Therapeutics (ATOS) released a preliminary analysis from a phase 2 trial of (Z)-endoxifen as part of the I-SPY 2 Endocrine Optimization Pilot, EOP, will be the subject of a poster presentation at the inaugural RISE UP Breast Cancer Conference in San Francisco, November 1-3, 2024. Atossa Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer. A preliminary data analysis from this study, which included 20 women with ER+/HER2- breast cancer who received 10mg of (Z)-endoxifen orally once daily for six cycles, showed that (Z)-endoxifen met the primary endpoint with 95 percent receiving greater than 75 % of planned treatment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ATOS:
- Atossa Therapeutics announces recognition of Breast Cancer Awarenss Month
- Atossa Therapeutics announces support of final rule from FDA
- Atos Shares Drop on Reduced Financial Targets
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
